Hollenbach Adams
Antibody production holds immense promise for addressing a plethora of health challenges, from combating infectious diseases to treating cancer. The scalability of production processes is crucial to meet the growing demand for these biopharmaceuticals. Stirred bioreactors are central to this endeavor, offering flexibility and efficiency. However, the scalability of antibody production in stirred bioreactors can be influenced by their geometries. This article explores innovative approaches to scaling antibody production in stirred bioreactors with differing geometries. It examines strategies such as advanced mixing techniques, optimization of mass transfer and novel reactor designs. These approaches aim to enhance productivity, improve process control and streamline manufacturing, ultimately advancing the accessibility of life-saving antibody therapies.
PDFShare this article
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report
